Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Wenkai Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2143-8680; OpenAlex author ID A5080225759. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2022: 4 papers · 2023: 8 papers · 2024: 2 papers

Papers 14

  1. Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030. First author DOI 10.1186/s12889-024-17875-6↗
  2. Global, regional and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044. Co-author DOI 10.3389/fonc.2024.1521788↗
  3. Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis. First author DOI 10.1080/21645515.2023.2269794↗
  4. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer. First author DOI 10.1155/2023/3419401↗
  5. Time trend of pancreatic cancer mortality in the Western Pacific Region: age-period-cohort analysis from 1990 to 2019 and forecasting for 2044. Co-author DOI 10.1186/s12885-023-11369-1↗
  6. Integrated transcriptomics, proteomics and metabolomics-based analysis uncover TAM2-associated glycolysis and pyruvate metabolic remodeling in pancreatic cance… Co-author DOI 10.3389/fimmu.2023.1170223↗
  7. The Global, Regional and National Burden of Pancreatic Cancer Attributable to Smoking, 1990 to 2019: A Systematic Analysis from the Global Burden of Disease St… Co-author DOI 10.3390/ijerph20021552↗
  8. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Reveals That TAM2-Driven Genes Affect Immunotherapeutic Response and Prognosis in Pancreatic … Co-author DOI 10.3390/ijms241612787↗
  9. Nomograms for Predicting the Risk and Prognosis of Liver Metastases in Pancreatic Cancer: A Population-Based Analysis. Co-author DOI 10.3390/jpm13030409↗
  10. Immunocyte Infiltration Analysis and Immunohistochemistry Identify EVL as a Potential Prognostic Biomarker for Pancreatic Cancer. Co-author DOI 10.3390/jpm13030433↗
  11. Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. Co-author DOI 10.1155/2022/4661929↗
  12. Neutrophils in pancreatic cancer: Potential therapeutic targets. Co-author DOI 10.3389/fonc.2022.1025805↗
  13. Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis. Last author DOI 10.3389/fphar.2022.979215↗
  14. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. First author DOI 10.3390/biom12101450↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wence Zhou · 11 shared papers, 2022–2024 · strength 2.42
  2. Yan Du · 6 shared papers, 2022–2023 · strength 1.34
  3. Xin Li · 5 shared papers, 2022–2023 · strength 1.03
  4. Shi Dong · 4 shared papers, 2022–2023 · strength 0.78
  5. Xiao Li · 2 shared papers, 2024 · strength 0.56
  6. Ru He · 2 shared papers, 2023–2024 · strength 0.48
  7. Zhou Chen · 2 shared papers, 2023 · strength 0.44
  8. Huaqing Shi · 2 shared papers, 2023 · strength 0.42
  9. Wence Zhou · 2 shared papers, 2023 · strength 0.42
  10. Shaozhen Rui · 1 shared paper, 2024 · strength 0.28
  11. Wenlong Zhang · 1 shared paper, 2022 · strength 0.22
  12. Jubao Niu · 1 shared paper, 2023 · strength 0.22
  13. Hui Zhang · 1 shared paper, 2023 · strength 0.22
  14. Xin Li · 1 shared paper, 2023 · strength 0.22
  15. Xiao Li · 1 shared paper, 2023 · strength 0.22
  16. Weixiong Zhu · 1 shared paper, 2022 · strength 0.19
  17. Hui Zhang · 1 shared paper, 2023 · strength 0.18
  18. Hui Tang · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.